A
Anand Padmanabhan
Researcher at Mayo Clinic
Publications - 75
Citations - 4156
Anand Padmanabhan is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Heparin-induced thrombocytopenia & Medicine. The author has an hindex of 20, co-authored 56 publications receiving 3236 citations. Previous affiliations of Anand Padmanabhan include Medical College of Wisconsin & Columbia University.
Papers
More filters
Journal ArticleDOI
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice—Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Sixth Special Issue
Joseph E. Schwartz,Jeffrey L. Winters,Anand Padmanabhan,Rasheed A. Balogun,Meghan Delaney,Michael L. Linenberger,Zbigniew M. Szczepiorkowski,Mark E. Williams,Yanyun Wu,Beth H. Shaz +9 more
TL;DR: The Eighth Edition of the JCA Special Issue seeks to continue to serve as a key resource that guides the utilization of TA in the treatment of human disease.
Journal ArticleDOI
Guidelines on the use of therapeutic apheresis in clinical practice - Evidence-based approach from the writing committee of the american society for apheresis
Joseph E. Schwartz,Jeffrey L. Winters,Anand Padmanabhan,Rasheed A. Balogun,Meghan Delaney,Michael L. Linenberger,Zbigniew M. Szczepiorkowski,Mark E. Williams,Yanyun Wu,Beth H. Shaz +9 more
TL;DR: This Sixth Edition of the ASFA Special Issue has further improved the process of using evidence‐based medicine in the recommendations by consistently applying the category and GRADE system definitions, but eliminating the “level of evidence” criteria.
Journal ArticleDOI
临床实践中治疗性单采术应用指南——基于美国血浆置换学会编写委员会的循证策略：第七版
Joseph E. Schwartz,Anand Padmanabhan,Nicole A. Aqui,Rasheed A. Balogun,Laura Connelly-Smith,Meghan Delaney,Nancy M. Dunbar,Volker Witt,Yanyun Wu,Beth H. Shaz +9 more
Journal ArticleDOI
Introduction to Special Issue: Clinical Applications of Therapeutic Apheresis: An Evidence Based Approach. 7th Edition
Joseph E. Schwartz,Anand Padmanabhan,Nicole A. Aqui,Rasheed A. Balogun,Laura Connelly-Smith,Meghan Delaney,Nancy M. Dunbar,Volker Witt,Yanyun Wu,Beth H. Shaz,Beth H. Shaz,Beth H. Shaz +11 more
Journal ArticleDOI
IVIg for Treatment of Severe Refractory Heparin-Induced Thrombocytopenia
Anand Padmanabhan,Curtis G. Jones,Shannon M. Pechauer,Brian R. Curtis,Daniel W. Bougie,Mehraboon S. Irani,Barbara J. Bryant,Jack B. Alperin,Thomas G. DeLoughery,Kevin P. Mulvey,Binod Dhakal,Renren Wen,Demin Wang,Richard H. Aster +13 more
TL;DR: IT patients with HIT who had severe thromboembolism and prolonged thrombocytopenia refractory to standard treatment but who achieved an immediate and sustained response to IVIg therapy are suggested to be considered for treatment.